MYGN Myriad Genetics Inc

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry.

“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics,” said Paul J. Diaz, President and CEO, Myriad Genetics. “In concert with our mission to advance health and well-being for all, we continue to execute our long-term strategic growth plan, driving sustained progress and impact. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease.”

Highlights of the report, which reflect the 21-month period of Jan. 1, 2023 through Sept. 30, 2024 (the “Reporting Period”), include:

• Continued operational excellence: Through a quality management system that documents our best practices, Myriad shared success in several categories including 88% of samples being processed within what we believe are industry-leading turnaround-times. Further, the company achieved a 72 net promoter score among current providers across its testing portfolio through July 2024.
• Commitment to innovation: Myriad continues to develop new technologies like molecular residual disease (MRD) assay and bring innovations to existing products. Its Labs of the Future initiative has resulted in modernized facilities that are expected to yield improved workflows, faster turnaround times and reduced operating costs.
• Being a good corporate partner: In addition to corporate governance, Myriad showcased its retention and recruitment, sustainability and community relations efforts. From a people standpoint, in 2024, 84% of employees said Myriad is a great place to work, which was 27 percentage points higher than the typical U.S. company. Further, in the Reporting Period, the company recycled 46.9 tons of plastic from its Salt Lake City laboratories.

For more information about Myriad’s quality, innovation and corporate responsibility, please read the report here.

About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement   This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the company's Labs of the Future are expected to yield improved workflows, faster turnaround times and reduced operating costs. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com 

Media Contact Glenn Farrell (385) 318-3718 PR@myriad.com